Scientists create PEG-free RNA nanoparticles that cut inflammation by 90%

Key Findings

🔄 Circular RNAs emerge as long-lasting vaccine platform

• Circular RNAs resist breakdown by cellular enzymes due to their closed-loop structure, potentially enabling single-dose vaccines

• These molecules support sustained protein translation through cap-independent mechanisms, unlike linear mRNA that degrades quickly

• Early studies suggest reduced immune activation compared to conventional mRNA, though rigorous head-to-head comparisons are still needed

🎯 Cancer vaccine achieves 42% complete tumor elimination in mice

• Researchers developed lipid nanoparticles that increased delivery to lymph nodes by 13.6-fold and spleen by 6.9-fold—key sites where immune responses begin

• The particles delivered both tumor antigen mRNA and immune-stimulating IL-12 directly into tumors

• In melanoma models, 42% of mice showed complete tumor clearance, outperforming standard commercial nanoparticles

🧪 Self-amplifying RNA vaccines reach phase 3 trials

• Self-amplifying RNA encodes its own copying machinery, enabling high antigen expression at substantially lower doses than conventional mRNA

• Several COVID-19 vaccines using this technology have completed phase 3 trials and received regulatory approval in multiple countries

• The platform requires 10-100 times less RNA than standard mRNA vaccines while potentially providing longer-lasting immunity

💊 Shellac coating enables oral RNA delivery

• Scientists used shellac—a natural resin—to protect RNA-carrying nanoparticles, achieving >90% encapsulation efficiency

• The coating enabled successful protein expression and gene editing in mice through both intravenous and oral administration

• Shellac-coated particles showed negligible toxicity while maintaining transfection across various cell types

🔬 Mass photometry provides rapid RNA vaccine quality control

• A new label-free technique can measure RNA vaccine molecular weight and detect impurities in minutes using minimal sample

• The method identified heterogeneous species difficult to resolve with traditional techniques, supporting both release testing and stability assessment

• Results showed good agreement with established analytical methods while requiring less sample and time

🌟 Influenza B vaccine protects against distant viral strains

• Mosaic hemagglutinin vaccines induced higher cross-reactive antibodies and CD4+ T cells compared to chimeric designs

• Vaccinated mice showed superior protection against the distantly related B/Lee/1940 strain in both passive transfer and direct challenge models

• The approach targets conserved viral regions to provide broader protection against diverse influenza B strains